Company
Every investor coverage indicates participated in a round Amplia Therapeutics raised.
Companies Amplia Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Gwo Yaw Ho | Lead Investigator | SMH Business, The Age Business |
| Dr Chris Burns | Chief Executive Officer and Managing Director | SMH Business, The Age Business |
Stories naming Amplia Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Amplia has locked in the design of its PRROSE phase two study pairing narmafotinib with chemotherapy in ovarian cancer, to run with ANZGOG across Australia and New Zealand, recruiting about 26 patients.
Biotech Amplia Therapeutics has completed planning for its PRROSE phase two trial pairing narmafotinib with chemotherapy in ovarian cancer, working with ANZGOG, with patient recruitment targeted before the end of 2026.
Roundup of Australian manufacturing news: OncoSil, K-TIG and Aurora Labs complete or commit raises, Amplia opens an offer, Siemens agrees to buy Altair, CSIRO unveils a printed-solar facility, and a WA medical alliance grows.
Roundup of Australian manufacturing briefs: Provaris bids for a hydrogen tank production cell, Lithium Australia wraps a share purchase plan, QEM launches a rights issue, and Laronix hires a speech pathologist.
Roundup of Australian manufacturing news: IDT Australia wins a Sanofi mRNA contract, Amplia collects an R&D tax refund, OptiGrid enters EnergyLab's accelerator, plus a ship launch, hydrogen towers, road works and a job listing.